Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1,661 GBX | +0.01% | -1.35% | +14.63% |
11:51am | Pfizer to Raise Around $4.27 Billion From Haleon Shares Sale -- Update | DJ |
11:45am | CAC40: new rebound after BoJ and ZEW indexes | CF |
Sales 2024 * | 31.56B 40.03B | Sales 2025 * | 33.49B 42.49B | Capitalization | 67.4B 85.49B |
---|---|---|---|---|---|
Net income 2024 * | 5.61B 7.11B | Net income 2025 * | 6.25B 7.93B | EV / Sales 2024 * | 2.53 x |
Net Debt 2024 * | 12.57B 15.95B | Net Debt 2025 * | 9.37B 11.88B | EV / Sales 2025 * | 2.29 x |
P/E ratio 2024 * |
12.1
x | P/E ratio 2025 * |
10.7
x | Employees | 70,212 |
Yield 2024 * |
3.68% | Yield 2025 * |
3.97% | Free-Float | 92% |
Latest transcript on GSK plc
1 day | +0.01% | ||
1 week | -1.35% | ||
Current month | -0.13% | ||
1 month | -0.41% | ||
3 months | +16.02% | ||
6 months | +10.61% | ||
Current year | +14.63% |
Managers | Title | Age | Since |
---|---|---|---|
Emma Walmsley
CEO | Chief Executive Officer | 55 | 10-04-30 |
Julie Brown
DFI | Director of Finance/CFO | 62 | 23-04-30 |
James Ford
CMP | Compliance Officer | - | 95-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Julie Brown
DFI | Director of Finance/CFO | 62 | 23-04-30 |
Jonathan Symonds
CHM | Chairman | 66 | 19-08-31 |
Urs Rohner
BRD | Director/Board Member | 65 | 14-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.17% | 11 M€ | +0.83% | - | |
3.15% | 18 M€ | +5.16% | - | |
2.51% | 4 M€ | +9.67% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-19 | 1,662 | +0.10% | 517 644 |
24-03-18 | 1,661 | +0.68% | 9,509,166 |
24-03-15 | 1,650 | -2.26% | 19,016,980 |
24-03-14 | 1,688 | -0.44% | 5,252,450 |
24-03-13 | 1,695 | +0.59% | 9,359,088 |
Delayed Quote London S.E., March 19, 2024 at 07:16 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.63% | 85.74B | |
+30.83% | 687B | |
+30.84% | 595B | |
+0.01% | 378B | |
+15.18% | 316B | |
+11.39% | 308B | |
+0.14% | 211B | |
-6.99% | 208B | |
-3.95% | 203B | |
-3.72% | 157B |